Management Team

Rick E Winningham
Chairman and Chief Executive Officer

Rick E Winningham has served as Chairman of the board of directors since July 2013. He has served as our Chief Executive Officer since our spin‑off from Theravance, Inc. (renamed Innoviva, Inc. in January 2016) in June 2014. From October 2001 to August 2014, Mr. Winningham served as Chief Executive Officer of Theravance, Inc., where he also served as Chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001 he served as President, Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network (“OTN”) and also as President of Global Marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol-Myers Squibb, Mr. Winningham also had full responsibility for Global Marketing in the Cardiovascular, Infectious Disease, Immunology, Oncology/Metabolics and GU/GI/Neuroscience therapeutic areas. Over a fifteen‑year period beginning in 1986 with BMS and its predecessor, Bristol‑Myers, Mr. Winningham held various U.S. and global management positions. Mr. Winningham served as a Director on the board of directors of the California Healthcare Institute (“CHI”) from November 2011 to March 2015. He was elected Chairman of CHI in January 2014, a position he held until CHI merged with Baybio to become the California Life Sciences Association (“CLSA”) in March 2015. Mr. Winningham was subsequently elected to the role of Chairman of CLSA in March 2015. He stepped down from the CLSA position in November 2015. He is a member of the board of directors of Jazz Pharmaceuticals plc, and a member of the board of directors of OncoMed Pharmaceuticals, Inc. Mr. Winningham is a member of Biotechnology Industry Organization’s board of directors and served on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham holds an M.B.A. from Texas Christian University and a B.S. degree from Southern Illinois University. 

Chairman of the Board
Renée D. Galá
Senior Vice President and Chief Financial Officer

Renée D. Galá joined Theravance Biopharma as Vice President, Finance and Treasurer in June 2014 in connection with our spinoff from Theravance, Inc., became Senior Vice President, Finance in July 2014 and became Senior Vice President and Chief Financial Officer in December 2014. Ms. Galá is responsible for finance and accounting, IT, and facilities activities. Prior to the SpinOff, Ms. Galá had been Vice President, Finance at Theravance, Inc. since January 2013. Ms. Galá joined Theravance, Inc. in June 2006, initially as Director of Financial Planning and Analysis and then as Senior Director of Finance and Procurement in July 2008. From 2001 to 2006, Ms. Galá worked at Eli Lilly and Company, where she held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development. Prior to joining Eli Lilly, she spent seven years in the energy industry in the U.S. and internationally in positions focused on corporate finance, project finance, and mergers and acquisitions. She is a member of the board of directors of Corcept Therapeutics Incorporated.  Ms. Galá earned a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School.

    Brett K. Haumann, M.D., M.B.A.
    Senior Vice President, Clinical Development and Chief Medical Officer

    Brett K. Haumann, M.D., M.B.A., joined Theravance Biopharma in June 2014 in connection with our spin‑off from Theravance, Inc., after joining Theravance, Inc. as Vice President, Clinical Development in October 2013. He became Vice President, Clinical Development and Operations of Theravance, Inc. in March 2014 and became Senior Vice President, Clinical Development at Theravance Biopharma in December 2014. Prior to joining Theravance, Inc., Dr. Haumann served as Chief Medical Officer at Circassia Limited. Previously, Dr. Haumann held senior positions at GlaxoSmithKline, including Medicines Development Leader and Vice President Clinical Development. Dr. Haumann has more than 15 years of experience in the discovery and development of pulmonary and allergy medicines. Dr. Haumann completed his M.D. at the University of Witwatersrand Medical School, South Africa and holds an M.B.A. from Open University, United Kingdom.

      Sharathchandra (Sharath) S. Hegde, Ph.D.
      Senior Vice President, Research

      Sharathchandra (Sharath) S. Hegde, Ph.D., joined Theravance Biopharma in June 2014 in connection with the spin‑off from Theravance, Inc. and became Senior Vice President, Research in March 2016. After joining Theravance, Inc. in September 1999, Dr. Hegde held various positions in the Pharmacology Department before being promoted to Vice President, Pharmacology in June 2007 and later becoming Vice President, Discovery Biology in June 2015. Prior to joining Theravance, Inc., Dr. Hegde spent 9 years at Syntex Corporation, later acquired by Roche Holdings Ltd. Dr. Hegde obtained his Ph.D. in Pharmacology from the University of Houston and obtained his B.Pharm/M.Pharm degree in Pharmacy/Pharmacology from the University of Bombay.

        Frank Pasqualone
        Senior Vice President and Global Head, Acute Care Business

        Frank Pasqualone joined Theravance Biopharma as Senior Vice President, Operations in June 2014 in connection with our spin‑off from Theravance, Inc. Prior to the Spin‑Off, Mr. Pasqualone held the position of Senior Vice President, Operations at Theravance, Inc. since January 2014. From 2010 to 2012, he served as President of Intercontinental Region: Latin America, Middle East and Africa and also as President of Southern Europe from 2009 to 2010, at Bristol‑Myers Squibb (“BMS”). Over a 25‑year period with BMS, Mr. Pasqualone held senior management positions in the U.S. and globally. In the U.S., he was responsible for the Oncology/Virology business and led the marketing group in the Diabetes business. Since leaving BMS and prior to joining Theravance, Mr. Pasqualone was self‑employed as a part‑time consultant. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.

          Kenneth R. Pitzer, D.V.M.
          Senior Vice President, Product Strategy and Commercial Planning

          Kenneth R. Pitzer, D.V.M., has served as our Senior Vice President, Product Strategy and Commercial Planning since March 2016. Previously, Dr. Pitzer was Vice President, Strategic and Commercial Planning since he joined Theravance Biopharma in October 2014 from Theravance, Inc., where he held the position of Vice President, Strategic and Commercial Planning since January 2008. Dr. Pitzer joined Theravance, Inc. in 2002 as Director, New Product Planning, and held various positions in the Commercial Development Department before being promoted to Vice President, Strategic and Commercial Planning in January 2008. Prior to joining Theravance, Inc. Dr. Pitzer worked at Lederle Laboratories in sales, marketing research and product management from 1989 to 1995 and then at Cygnus, Inc., from 1995 until 2002, ultimately serving as the Vice President of Product Management. Dr. Pitzer earned a Doctor of Veterinary Medicine degree from The Ohio State University in 1987 and an M.B.A. from Carnegie‑Mellon University in 1989.

            Vijay Sabesan
            Vice President of Technical Operations

            Vijay Sabesan is the Vice President of Technical Operations at Theravance Biopharma. He joined the company in June 2014 in connection with the spin-off from Theravance, Inc. (now Innoviva, Inc.). With Theravance, Inc. from 2004 to 2014, he held various positions before serving as the Senior Director of Process R&D. Prior to joining Theravance, Inc., Mr. Sabesan worked in the chemical process development group at Schering-Plough Research Institute, later acquired by Merck. Mr. Sabesan has a B.Tech. in Chemical Engineering from the Indian Institute of Technology, Madras, and an M.S. in Chemical Engineering from Rutgers University.

              Bradford J. Shafer
              Executive Vice President and General Counsel

              Bradford J. Shafer has served as our Executive Vice President, General Counsel since March 2016 and our Secretary since November 2014. Previously, he was our Senior Vice President, General Counsel since September 2014. Prior to joining Theravance Biopharma, Mr. Shafer served as Senior Vice President, General Counsel and Secretary at Theravance, Inc., since August 1999. From 1996 to 1999 he served as General Counsel of Heartport, Inc., a cardiovascular medical device company. From 1993 to 1996, Mr. Shafer was a partner in the Business and Technology Group at the law firm of Brobeck, Phleger & Harrison LLP. Mr. Shafer holds a J.D. from the University of California, Hastings College of the Law, where he was Editor‑in‑Chief of The Hastings Constitutional Law Quarterly, and a B.A. from the University of the Pacific, where he graduated magna cum laude.

                Shehnaaz Suliman, M.D., M.Phil., M.B.A.
                Senior Vice President, Corporate Development and Strategy

                Shehnaaz Suliman, M.D., M.Phil., M.B.A., joined Theravance Biopharma as Senior Vice President, Corporate Development and Strategy in July 2017, where she is responsible for leading the company’s business development activities and corporate strategy, including identifying and executing strategic transactions to drive value. Prior to joining Theravance Biopharma, Dr. Suliman was Vice President and Global Therapeutic Head, Roche Partnering based at Genentech since May 2015 where she led a global team focused on strategic licensing and acquisition transactions. Since September 2010, Dr. Suliman was a Group Leader and Project Team Leader in the Genentech R&D Portfolio Management and Operations Group with oversight for early and clinical drug development programs in immunology, infectious diseases, neurosciences, cardiovascular, metabolism and ophthalmology. Prior to that, Dr. Suliman held various management roles at Gilead Sciences over a period of six years since January 2005, where she played a leading role in defining and executing Gilead’s licensing, mergers and acquisitions strategy into new therapeutic areas. Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners prior to Gilead, advising public and private companies on buy- and sell-side transactions from 2002-2004. Dr. Suliman received her M.D. at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and Masters in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.

                  Philip D. Worboys, Ph.D.
                  Senior Vice President, Translational Science

                  Philip D. Worboys, Ph.D., has served as our Senior Vice President, Translational Science since March 2016, where he is responsible for leading the progression of drug candidates from the discovery stage into human clinical studies, including clinical pharmacology and biomarker development as well as project management. Previously, Dr. Worboys was Vice President, Drug Metabolism and Pharmacokinetics (“DMPK”) since he joined Theravance Biopharma in October 2014 from Theravance, Inc., where he held the position of Vice President, DMPK since November 2008. Prior to joining Theravance, Inc., he served as Senior Director, DMPK at Roche Bioscience, Inc. since 2005. From 2001 to 2005, Dr. Worboys was Senior Director, DMPK at Pfizer and an Associate Director, DMPK at Pharmacia. He spent the first part of his career in DMPK, at Merck Sharp & Dohme in Harlow, United Kingdom, and worked in various capacities at Aventis, Unilever and GlaxoSmithKline prior to that. Dr. Worboys obtained his Ph.D. degree in Pharmaceutics from Manchester University, United Kingdom. He holds a B.Sc. degree in Biochemistry from Imperial College of Science, Technology & Medicine at the University of London.

                    Dennis O. Driver
                    Vice President and Chief Human Resources Officer

                    Dennis O. Driver is the Vice President and Chief Human Resources Officer of Theravance Biopharma. Mr. Driver joined the company in September 2014, after serving as Vice President, Human Resources of Theravance, Inc. (now called Innoviva, Inc.) since October 2007. From 2001 through 2007, Mr. Driver served as Vice President, Human Resources at various companies within the Johnson & Johnson family of businesses including Biosense Webster, Inc., Scios Inc. and Cordis Corporation. Prior to that, he held senior level human resources leadership positions with PeopleSoft, Silicon Graphics, Inc. and Acuson Corporation. He has a wealth of human resources expertise in both domestic and international operations. Mr. Driver holds a B.A. in Business Administration from Stillman College, where he graduated summa cum laude. Mr. Driver served as an officer in the United States Marine Corps.